View Clinical Trial (Medical Research Study)
Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure - NCT00665977-63143(Clinical Trial 217425)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
St. Louis |
|
State:
|
|
MO |
| Zip Code: |
|
63143 |
| Conditions: |
|
Obstructive Sleep Apnea - Nasal Congestion - Sinus Congestion |
| Purpose: |
|
1. CPAP compliance will be significantly higher in both the heated humidity with
Thermosmart™ and the nasal steroid phases compared to the double placebo phase.
2. CPAP compliance will be comparably improved in the heated humidity with Thermosmart™
phase versus the nasal steroid phase.
3. Improvement in nasal symptoms in using CPAP will be significantly improved in both the
heated humidity with Thermosmart™ and the nasal steroid phases compared to the double
placebo phase, and comparable between the heated humidity with Thermosmart™ phase
versus the nasal steroid phase.
4. Secondary to improvements in CPAP compliance, measures of daytime functioning and
quality of life will improve in the heated humidity with Thermosmart™ versus double
placebo.
|
| Study summary: |
|
Eligible participants will undergo this double-blind, placebo controlled, single-blind
double placebo run-in, crossover trial to determine the efficacy of heated humidity with
Thermosmart™ in improving compliance and nasal symptoms in patients using CPAP versus a
nasal steroid and placebo (heated humidity, nasal steroid placebo) phases. After successful
screening, participants will undergo a two week single-blind double placebo run-in phase
using heated humidity and a nasal steroid placebo. The double-blind treatment phase will
last a total of six weeks. Participants will undergo both phases: three weeks using heated
humidity with Thermosmart™ and nasal steroid placebo and three weeks using a nasal steroid
with a heated humidifier. Treatment phases will be counterbalanced. Study participation
will last a total of 8 weeks from screening to completion of double-blind treatment. |
| Criteria: |
|
Inclusion Criteria:
- Between the ages of 18-65
- Diagnosis of obstructive sleep apnea (OSA) with apnea/hypopnea index (AHI) > 15/hr
- Currently using CPAP therapy and within 3 weeks to 12 months of initial CPAP
titration
- Based on the CPAP nasal symptom questionnaire, a score of at least 3 (sometimes) for
at least one of the following nasal symptoms related to their sleep apnea and CPAP
usage: nasal congestion, runny nose, sneezing, or nasal irritation
- Willingness to tolerate and continue therapy with nCPAP
- Successfully titrated on nCPAP in a sleep center to a pressure between 6-16 cmH2O
- Willingness to comply and complete study related procedures
- Fluent in the English language
Exclusion Criteria:
- Co-morbid medical condition that is either medically significant and unstable, would
interfere with the patient's ability to routinely use CPAP, or is a contraindication
for use of a nasal steroid
- Women who are pregnant or who may potentially become pregnant during the course of
the research trial.
- CPAP compliance over the past three weeks at screening > 5 hours/night, suggesting no
compromised CPAP usage due to adverse nasal symptoms
- Wake resting SaO2 < 90%
- Currently using Bi-Level therapy, supplemental oxygen with CPAP therapy, or using a
pressure outside inclusion criteria
- Currently using a Full-Face mask for CPAP therapy
- Current or prior use of the Fisher Paykel 604 CPAP machine with Thermosmart™ heated
humidity.
- Patients who were never prescribed a heated humidifier with their CPAP machine (i.e.
no humidifier or passover humidifier).
- Intranasal steroid treatment within the previous six months. Patient's currently
taking intranasal steroid treatment cannot wash-out of steroid treatment to be
included nor if patients have used nasal steroid treatment while on CPAP therapy
- Current upper airway tract infection, influenza, respiratory infection at time of
screening or nasal surgery within 90 days of screening
- Prior surgical intervention for obstructive sleep apnea
- Currently taking medications that would be contraindicated to using a nasal steroid.
Patients taking hypnotic or wake promoting therapy can participate if they have been
on a stable dose prior to CPAP therapy and willing to maintain current dose as
prescribed.
- Shift or rotating shift workers or individuals who routinely cannot contribute at
least 6 hours/night to sleep/attempting therapy
- Additional sleep disorder that would interfere with routine use of CPAP |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
July 2, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|